Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions

2020 ◽  
Author(s):  
Claudia E. Weber ◽  
Matthias Kraemer ◽  
Andreas Dabringhaus ◽  
Anne Ebert ◽  
Michael Platten ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Venous Diameter ◽  
Active Multiple Sclerosis

First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria

2017 ◽  
Vol 381 ◽  
pp. 796
Author(s):  
F. Otto ◽  
B. Bajer-Kornek ◽  
P. Rommer ◽  
F. Leutmezer ◽  
C. Franta-Elmer ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Line Treatment ◽  
First Line ◽  
Post Marketing ◽  
First Line Treatment ◽  
Active Multiple Sclerosis

Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis

2004 ◽  
Vol 11 (7) ◽  
pp. 445-449 ◽  
Author(s):  
T. L. Sorensen ◽  
R. M. Ransohoff ◽  
R. M. Strieter ◽  
F. Sellebjerg
Keyword(s):  
Multiple Sclerosis ◽  
Chemokine Receptor ◽  
Active Multiple Sclerosis ◽  
Chemokine Receptor Ccr2

scholarly journals Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

2021 ◽  
pp. 135245852110521
Author(s):  
Alyssa A Toorop ◽  
Theo Rispens ◽  
Eva MM Strijbis ◽  
Bob W van Oosten ◽  
Brigit A de Jong ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Third Trimester ◽  
Blood Samples ◽  
The Third ◽  
Trough Concentrations ◽  
Active Multiple Sclerosis

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1

2002 ◽  
Vol 129 (1-2) ◽  
pp. 205-215 ◽  
Author(s):  
Xuan Feng ◽  
Anthony L Petraglia ◽  
Michael Chen ◽  
Paul V Byskosh ◽  
Markus D Boos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Stimulated Genes ◽  
Low Expression ◽  
Active Multiple Sclerosis

Natalizumab for the treatment of highly active multiple sclerosis: risks and benefits

2019 ◽  
Vol 15 (5) ◽  
pp. 216-222
Author(s):  
Nicola Daykin
Keyword(s):  
Multiple Sclerosis ◽  
Gold Standard ◽  
Risk Profile ◽  
Risks And Benefits ◽  
Highly Active ◽  
History Of ◽  
The Uk ◽  
Highly Active Multiple Sclerosis ◽  
Active Multiple Sclerosis

This article discusses the history of natalizumab (Tysabri), the first monoclonal antibody used to treat multiple sclerosis. It reviews how the medication's difficult beginnings and controversial past have changed how this treatment is monitored. The article looks at the role of clinicians in maintaining patient safety, the benefits and risk profile of this treatment and ways of optimising practice to provide gold standard nationalised natalizumab services throughout the UK.

Highly active multiple sclerosis: An update

2019 ◽  
Vol 30 ◽  
pp. 215-224 ◽  
Author(s):  
Cindy Díaz ◽  
Luis Alfonso Zarco ◽  
Diego M. Rivera
Keyword(s):  
Multiple Sclerosis ◽  
Highly Active ◽  
Highly Active Multiple Sclerosis ◽  
Active Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document